T

TScan Therapeutics Inc
NASDAQ:TCRX

Watchlist Manager
TScan Therapeutics Inc
NASDAQ:TCRX
Watchlist
Price: 1.105 USD -1.34%
Market Cap: $62.7m

Operating Margin

-1 778%
Current
Declining
by 351.7%
vs 3-y average of -1 426.3%

Operating Margin shows how much profit a company makes from its regular business activities after covering operating costs. It helps measure how efficiently the company turns sales into profit.

Operating Margin
-1 778%
=
Operating Income
$-149.8m
/
Revenue
$8.4m

Operating Margin shows how much profit a company makes from its regular business activities after covering operating costs. It helps measure how efficiently the company turns sales into profit.

Operating Margin
-1 778%
=
Operating Income
$-149.8m
/
Revenue
$8.4m

Peer Comparison

Country Company Market Cap Operating
Margin
US
TScan Therapeutics Inc
NASDAQ:TCRX
63.6m USD
Loading...
FR
Pharnext SCA
OTC:PNEXF
6T USD
Loading...
US
Abbvie Inc
NYSE:ABBV
395.8B USD
Loading...
US
Amgen Inc
NASDAQ:AMGN
187.7B USD
Loading...
US
Gilead Sciences Inc
NASDAQ:GILD
175.1B USD
Loading...
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
120.4B USD
Loading...
US
Epizyme Inc
F:EPE
94.1B EUR
Loading...
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
80.6B USD
Loading...
AU
CSL Ltd
ASX:CSL
87.1B AUD
Loading...
NL
argenx SE
XBRU:ARGX
44B EUR
Loading...
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
46.8B USD
Loading...

Market Distribution

Lower than 95% of companies in the United States of America
Percentile
5th
Based on 14 112 companies
5th percentile
-1 778%
Low
-4 087 900% — -5.1%
Typical Range
-5.1% — 14.8%
High
14.8% — 1 032 600%
Distribution Statistics
the United States of America
Min -4 087 900%
30th Percentile -5.1%
Median 6%
70th Percentile 14.8%
Max 1 032 600%

TScan Therapeutics Inc
Glance View

Market Cap
62.7m USD
Industry
Biotechnology

TScan Therapeutics, Inc. discovers and develops transformative T cell therapies (TCR-T) to treat liquid cancers, solid tumors and other serious diseases. The company is headquartered in Waltham, Massachusetts and currently employs 104 full-time employees. The company went IPO on 2021-07-16. The firm is focused on developing a pipeline of T cell receptor-engineered T cell (TCR-T) therapies for the treatment of patients with cancer. The firm's lead liquid tumor TCR-T therapy candidates include TSC-100 and TSC-101, which are in development for the treatment of patients with hematologic malignancies to eliminate residual leukemia and prevent relapse after hematopoietic stem cell transplantation (HCT). TSC-100 and TSC-101 targets histocompatibility antigens (HA)-1 and HA-2 antigens, respectively. TScan solid tumor product candidates include TSC-200, TSC-201, TSC-202 and TSC-203. Its TSC-200 series of product candidates are being developed to treat both HPV-positive and HPV-negative tumors. The firm's platform technologies include TargetScan, ReceptorScan and T-Integrate.

TCRX Intrinsic Value
0.923 USD
Overvaluation 16%
Intrinsic Value
Price
T
What is Operating Margin?
Operating Margin shows how much profit a company makes from its regular business activities after covering operating costs. It helps measure how efficiently the company turns sales into profit.
How is Operating Margin calculated?

Operating Margin is calculated by dividing the Operating Income by the Revenue.

Operating Margin
-1 778%
=
Operating Income
$-149.8m
/
Revenue
$8.4m
What is TScan Therapeutics Inc's current Operating Margin?

The current Operating Margin for TScan Therapeutics Inc is -1 778%, which is below its 3-year median of -1 426.3%.

How has Operating Margin changed over time?

Over the last 3 years, TScan Therapeutics Inc’s Operating Margin has decreased from -467.9% to -1 778%. During this period, it reached a low of -4 787.7% on Dec 31, 2024 and a high of -422.7% on Mar 31, 2023.

Back to Top